Biocon has received approval for issuance of commercial papers up to an amount not exceeding Rs 600 crore in one or more tranches on private placement basis. The Board of Directors at its meeting held on April 04, 2025, has approved the same.
Earlier, the company’s wholly owned subsidiary -- Biocon Pharma had received approval from the U.S Food and Drug Administration (USFDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
